PMID- 35875080
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220726
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Exploring the Pharmacological Mechanism of the Effective Chinese Medicines 
      Against Gynecological Cancer Based on Meta-Analysis Combined With Network 
      Pharmacology Analysis.
PG  - 817772
LID - 10.3389/fonc.2022.817772 [doi]
LID - 817772
AB  - This meta-analysis plus network pharmacology aimed to investigate whether 
      traditional Chinese medicine (TCM) combined with chemotherapy is associated with 
      more beneficial efficacy data in the treatment of gynecological cancer (GC). A 
      total of 11 randomized controlled trials (RCTs) consisting of 863 GC patients 
      were included. Results showed a better ORR (RR: 1.42, 95% CI: 1.18-1.71; I 
      (2) = 21.4%; p = 0.282), DCR (RR: 1.13, 95% CI: 1.03-1.25; I (2) = 0.0%; 
      p = 0.492), PD (RR: 0.27, 95% CI: 0.11-0.65, p = 0.003; I (2) = 0.0%, p = 0.930), 
      and QOL (SMD: 0.85, 95% CI: 0.38-1.33, p = 0.005) and higher proportions of 
      CD3(+) T (WMD: 5.65, 95% CI: 4.23-7.08, p = 0.000; I (2) = 68.3%, p = 0.004), 
      CD4(+) T (WMD: 6.97, 95% CI: 5.35-8.59, p = 0.000; I (2) = 83.4%, p = 0.000), and 
      the CD4(+)/CD8(+) T ratio (WMD: 0.32, 95% CI: 0.23-0.42, p = 0.000; I 
      (2) = 78.0%, p = 0.000). The number of adverse events (AEs) was significantly 
      lower in the TCM + chemotherapy group. The active components and targets of 19 
      high-frequency Chinese medicines obtained from the meta-analysis were screened 
      and explored in network pharmacology analysis. Also, a regulatory network of 
      active components and targets, a core network and key genes, a diagram of protein 
      interaction, network topology analysis, and gene body GO function and KEGG 
      pathway enrichment analysis were performed. A total of 120 active components were 
      identified. NPM1 and HSPA8 are the most critical target proteins in the core 
      network of protein interaction. HSP90AA1 is the most important target protein in 
      the TCM group. KEGG enrichment analysis showed that it was highly significant in 
      the lipid and atherosclerotic pathways. Therefore, moderate evidence revealed 
      that TCM plus chemotherapy has obvious advantages over chemotherapy alone in 
      terms of tumor responses, QOL, peripheral blood lymphocyte levels, and fewer AEs 
      in the treatment of GC. The potential important targets and core genes were 
      displayed. SYSTEMATIC REVIEW REGISTRATION: www.crd.york.ac.uk/PROSPERO/, 
      identifier CRD42021252500.
CI  - Copyright (c) 2022 Ren, Yu, Qian, Ye, Zhu, Yu, Sun and Zhang.
FAU - Ren, Ning
AU  - Ren N
AD  - Hangzhou TCM Hospital of Zhejiang Chinese Medical University (Hangzhou Hospital 
      of Traditional Chinese Medicine), Hangzhou, China.
FAU - Yu, Lulin
AU  - Yu L
AD  - The First School of Clinical Medicine, Zhejiang Chinese Medical University, 
      Hangzhou, China.
FAU - Qian, Lihui
AU  - Qian L
AD  - The First School of Clinical Medicine, Zhejiang Chinese Medical University, 
      Hangzhou, China.
FAU - Ye, Gewei
AU  - Ye G
AD  - The First School of Clinical Medicine, Zhejiang Chinese Medical University, 
      Hangzhou, China.
FAU - Zhu, Zhenzheng
AU  - Zhu Z
AD  - The First School of Clinical Medicine, Zhejiang Chinese Medical University, 
      Hangzhou, China.
FAU - Yu, Jieru
AU  - Yu J
AD  - School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, 
      China.
FAU - Sun, Leitao
AU  - Sun L
AD  - Department of Medical Oncology, The First Affiliated Hospital of Zhejiang Chinese 
      Medical University (Zhejiang Provincial Hospital of Traditional Chinese 
      Medicine), Hangzhou, China.
FAU - Zhang, Leyin
AU  - Zhang L
AD  - Department of Oncology, Hangzhou TCM Hospital of Zhejiang Chinese Medical 
      University (Hangzhou Hospital of Traditional Chinese Medicine), Hangzhou, China.
LA  - eng
PT  - Systematic Review
DEP - 20220706
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9298573
OTO - NOTNLM
OT  - chemotherapy
OT  - gynecological cancer
OT  - meta-analysis
OT  - network pharmacology
OT  - traditional Chinese medicine
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/07/26 06:00
MHDA- 2022/07/26 06:01
PMCR- 2022/01/01
CRDT- 2022/07/25 04:04
PHST- 2021/11/18 00:00 [received]
PHST- 2022/06/01 00:00 [accepted]
PHST- 2022/07/25 04:04 [entrez]
PHST- 2022/07/26 06:00 [pubmed]
PHST- 2022/07/26 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.817772 [doi]
PST - epublish
SO  - Front Oncol. 2022 Jul 6;12:817772. doi: 10.3389/fonc.2022.817772. eCollection 
      2022.